VERTEX PHARMACEUTICALS
Lobbying client. Federal LDA filings.
Connected on the graph
Inbound (27)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| — | Kate Kalutkiewicz | lobbied_for | — | lda_lobbyist_client | |
| — | Matthew O Schumaker | lobbied_for | — | lda_lobbyist_client | |
| — | Joshua David Odintz | lobbied_for | — | lda_lobbyist_client | |
| — | Swarna Vallurupalli | lobbied_for | — | lda_lobbyist_client | |
| — | Kyle Hill | lobbied_for | — | lda_lobbyist_client | |
| — | Adam Buckalew | lobbied_for | — | lda_lobbyist_client | |
| — | Adam Buckalew | lobbied_for | — | lda_lobbyist_client | |
| — | Hazen Clay Marshall | lobbied_for | — | lda_lobbyist_client | |
| — | Michael Hayes | lobbied_for | — | lda_lobbyist_client | |
| — | Laura Friedel | lobbied_for | — | lda_lobbyist_client | |
| — | Veronica Jackson | lobbied_for | — | lda_lobbyist_client | |
| — | Hannah Beth Cornwell | lobbied_for | — | lda_lobbyist_client | |
| — | Monica Popp | lobbied_for | — | lda_lobbyist_client | |
| — | Andrew Joseph Siracuse | lobbied_for | — | lda_lobbyist_client | |
| — | Mike Mckay | lobbied_for | — | lda_lobbyist_client | |
| — | E. Brandon Garrett | lobbied_for | — | lda_lobbyist_client | |
| 2026-01-01 | ALSTON & BIRD LLP | lobbies_for | — | lda_filing | |
| 2026-01-01 | VERTEX PHARMACEUTICALS INCORPORATED | lobbies_for | $1,140,000 | lda_filing | |
| 2026-01-01 | HOLLAND & KNIGHT LLP | lobbies_for | $20,000 | lda_filing | |
| 2026-01-01 | MARSHALL & POPP, LLC | lobbies_for | $60,000 | lda_filing | |
| 2026-01-01 | ALB SOLUTIONS | lobbies_for | — | lda_filing | |
| 2026-01-01 | ALB SOLUTIONS | lobbies_for | $50,000 | lda_filing | |
| 2026-01-01 | EMPIRE CONSULTING GROUP | lobbies_for | $50,000 | lda_filing | |
| 2026-01-01 | SALT POINT STRATEGIES | lobbies_for | $10,000 | lda_filing | |
| 2025-01-01 | MARSHALL & POPP, LLC | lobbies_for | — | lda_filing | |
| 2025-01-01 | SALT POINT STRATEGIES | lobbies_for | — | lda_filing | |
| 2025-01-01 | MCLARTY INBOUND LLC | lobbies_for | — | lda_filing |
Outbound (8)
| date | type | to | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | lobbies_on_bill | HR 1227 — Alternatives to PAIN Act | — | H.R. 1227 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1414 — Cameron’s Law | — | H.R. 1414 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1518 — New Era of Preventing End-Stage Kidney Disease Act | — | H.R. 1518 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 6423 — HELP Copays Act | — | H.R. 6423 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 475 — Alternatives to PAIN Act | — | S. 475 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1227 — Alternatives to PAIN Act | — | H.R. 1227 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 475 — Alternatives to PAIN Act | — | S.475 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | HR 1227 — Alternatives to PAIN Act | — | HR 1227 | lobbying_bill_mention |
- Source id
64435- General description
- Biopharmaceutical company.
- State
- MA
- Country
- US
- Principal place of business
- US
- Effective date
- 2025-02-06
- Total spend (across 2 ingested filings)
- $10,000
Filings
| Posted | Type | Year | Lobbying firm | Income |
|---|---|---|---|---|
| 2026-04-17 | 1T | 2026 | SALT POINT STRATEGIES | $10,000 |
| 2025-02-24 | RR | 2025 | SALT POINT STRATEGIES | — |